Pharmacological inhibition of ENPP2 signalling to treat pulmonary fibrosis reached phase 3 clinical trials (ClinicalTrials.gov Identifier: NCT03711162), although there are no studies published on tendon. The gene discussed is ENPP2; the disease is pulmonary fibrosis.